Clinical Trial Program
Ablative Solutions is studying Dehydrated Alcohol Injection, USP administered with the Peregrine SystemTM Infusion Catheter for transcatheter alcohol-mediated renal denervation for the treatment of uncontrolled hypertension with targeted delivery of alcohol.
For complete trial details, select the logo below to visit ClinicalTrials.gov.
RADAR Clinical Trial
Under an Investigational New Drug (IND) application, the RADAR Clinical Study is a randomized, blinded, sham-controlled clinical study evaluating the safety and effectiveness of alcohol-mediated renal denervation using Dehydrated Alcohol Injection, USP administered with the Peregrine System™ Infusion Catheter in adults with hypertension. Enrollment in the RADAR multi-center trial began in U.S. in 2026.
Target BP I Clinical Trial
The global TARGET BP I trial was a multi-center, blinded, randomized, sham-controlled trial to evaluate the safety and efficacy of ASI’s drug-device combination therapy for the treatment of uncontrolled hypertension despite pharmacologic treatment.
Enrollment and follow up of subjects in this study is complete.
Target BP OFF-MED Clinical Trial
The TARGET BP OFF-MED Clinical Trial evaluated Dehydrated Alcohol Injection, USP administered with the Peregrine SystemTM Infusion Catheter in patients who are either not taking anti-hypertension medications for elevated blood pressure or for patients whose anti-hypertension medications have been removed.
Enrollment and follow up of subjects in this study is complete.